Zusammenfassung
Die benigne Prostatahyperplasie — obgleich eigentlich eine histologische Diagnose — hat lange Zeit als Überbegriff für die klinische Definition einer vergrößerten Prostata mit assoziierten Miktionsbeschwerden gedient. Nach den aktuellen Leitlinien der Deutschen Urologen sollte für das bisher mit „Benigne Prostatahyperplasie (BPH)“ bezeichnete Krankheitsbild fortan die Bezeichnung „Benignes Prostata-Syndrom (BPS)“ Verwendung finden, um damit einen neuen Überbegriff für die pathophysiologisch sehr variable Relation zwischen Miktionssymptomatik (lower urinary tract Symptoms, LUTS), Prostatavergrößerung (benign prostatic enlargement, BPE) und Obstruktion (bladder outlet obstruction, BOO, bzw. benign prostatic obstruction, BPO) zu etablieren (Leitlinien 2003a). Die alte Bezeichnung „BPH“ sollte — wie im TNM-System — als „pBPH“ (p für pathologisch-histologisch) gekennzeichnet und ausschließlich in diesem Kontext verwendet werden. Differenzialdiagnostisch sind nicht durch eine BPH bedingte Miktionssymptome auszuschließen. Letztlich muss die Diagnostik klären, in welchem Verhältnis Miktionssymptome (LUTS), eine Obstruktion des Blasenauslasses (BOO) infolge einer benignen Prostataobstruktion (BPO) und die Vergrößerung der Prostata (BPE) per se stehen (Leitlinien 2003a).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Anderson B, Roehrborn CG, Schalken JA, Emberton M (2001) The progression of benign prostatic hyperplasia: examining the evidence and determing the risk. Eur Uro 139: 390–399
Arrighi HM, Metter EJ, Guess HA, Fozzard JL (1991) Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 38 (Suppl): 4–8
Bautista OM, Kusek JW, Nyberg LM et al. (2003) Study design of the medical therapy of prostatic symptoms (MTOPS) trial. Control Clin Trials 24: 224–243
Berges RR, Pientka L (1999) Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 36 (Suppl3): 21–27
Berges RR, Pientka L, Hofner K, Senge T, Jonas U (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Uro I 39:682–687
Delakas D, Lianos E, Karyotis I, Cranidis A (2001) Finasteride: a longterm follow-up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urol lnt 67: 69–72
Dreikorn K, Berges R, Pientka L, Jonas U (2002) Phytotherapie bei BPH. Urologe A 41: 447–451
Edwards JE, Moore RA (2002) Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomized trials. BMC Urology 2: 14
Fornara P, Semjonow A (2002) PSA: Der Weg zum Befund. Zuckschwerdt, Munchen, pp 1–15
Gaynor ME (2003) Isoflavones and the prevention and treatment of prostate disease. Cleveland Clinic J Med 70: 203–216
Gerber G (2002) Phytotherapy for benign prostatic hyperplasia. Current Urol Rep 3: 285–291
Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM (1999) Association of health-related quality of life and benign prostatic enlargement. Eur Uro 135: 277–284
Gonzalez CM, McVary KT (2003) The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 4: 276–281
Jacobsen SJ, Girman CJ, Guess HA et al. (1993) Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology 1993 42: 663–671
Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM (1999) Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 162: 1301–1306
Jacobsen SJ, Girman CJ, Lieber MM (2001) Natural history of benign prostatic hyperplasia. Urology 58 (Suppl 1): 5–16
Klein EA (2003) Supplements and the prostate: Widespread use, little evidence. Cleveland Clinic J Med 70: 169–176
Larsen TR (2003) Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology 61: 692–698
Leitlinien (2003a): Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms (BPS). Urologe 42: 584–590
Leitlinien (2003b): Leitlinien der Deutschen Urologen zur Therapie des benignen Prostatasyndroms (BPS). http://www.uniduesseldorf. de/AWMF/ll/index.html
Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB (2001) Riskfactors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54: 935–944
Prezioso D, Catuogno C, Galassi P, D’Andrea G, Castello G, Pirritano D (2001) Life-style in patients with LUTS suggestive of BPH. Eur Urol 40 (Suppl 1): 9–12
Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM (1999) Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 161: 1174–1179
Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM (1997) Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 157: 1711–1717
Roehrborn CG (2002) Are all alpha-blockers created equal? An update. Urology 59 (Suppl 2A): 3–6
Roehrborn CG, Bruskewitz R, Nickel GC et al. (2000) Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS study group. Eur Urol 37: 528–536
Roehrborn CG, Malice M, Cook TJ, Girman CJ (2001) Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58: 210–216
Roehrborn CG, Boyle P, Nickel JE, Hoefner K, Andriole G; ARIA3001, ARIA3002 and ARIA3003 Study Investigators (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60: 434–441
Sakeland J, Sakeland A (2003) Naturheilverfahren in der Urologie. Springer, Berlin Heidelberg New York Tokio, pp 103–127
Wessells H, Roy J, Bannow J et al. (2003) Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 61: 579–584
Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan DW, Carter HB (2002) Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 167: 2484–2487
Adolfsson J (1995) Radical prostatectomy, radiotherapy or deferred treatment for localized prostate Cancer? Cancer Surv 23:141–148
Arzneimittelkommission (2000): Arzneimittelkommission der deutschen Ärtzeschaft. Hinweise zur sicheren Verordnung von Sildenafil (Viagra). Dtsch Ärztebl 97: A199
Bales GT, Chodak GW (1996) A controlled trial of bicalutamide versus castration in patients with advanced prostate Cancer. Urology 41:38–43
Benson M, Whang I, Pantuck A et al. (1992) Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate Cancer. J Urol 147:815–821
Blute ML, Zincke H, Farrow GM (1986) Long-term followup of young patients with stage A adenocarcinoma of the prostate. J Urol 136: 840–843
Brawer M, Chetner M (1997) Ultrasonography of the prostate and biopsy. In: Walsh P et al. (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2506–2518
Brawer MK, Cheli CD, Neaman IE et al. (2000) Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate Cancer. J Urol 163:1476–1480
Carter H, Pearson J (1993): PSA velocity for the diagnosis of early prostate Cancer. Urol Clin North Am 20:665–670
Carter H, Partin A (1997) Diagnosis and Staging of prostate Cancer. In: Walsh P et al. (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2519–2537
Catalona WJ, Smith DS (1994) 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate Cancer. JUrol 152:1837–1842
Catalona WJ, Partin AW, Slawin KM et al. (1998) Use the percentage of free prostate-specific antigen to enhance differentiation of prostate Cancer from benign prostatic disease. JAMA 279:1542–1547
Collins GN, Lloyd SN, Hekir M, McKelvie GB (1993) Multiple transrectal ultrasound-guided prostatic biopsies-true morbidity ans acceptance. Br JUrol 71:460–463
Davidson PJ, Hop W, Kurth KH et al. (1995) Progression in untreated Carcinoma of the prostate metastatic to regional lymph nodes (stage tO to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 154: 2118–2122
De Koning HJ, Liem MK, Baan CA et al. (2002) Prostate Cancer mortality reduction by Screening: Power and time frame with complete enrollment in the european randomised Screening for prostate Cancer (ERSPC) trial. Int J Cancer 98:268–273
Eichholzer M, Stahelin HB, Ludin E, Bernasconi F (1999) Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate Cancer: seventeen-year follow-up of the prospective basel study. Prostate 38:189–198
Epstein JI, Oesterling JE, Walsh PC (1988) The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage A1 prostate Cancer. J Urol 139:975–9
Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathological and clinical findings to predict tumor extent of non-palpable (stage T1 c) prostate Cancer. JAMA 271:368–374
Fachgesellschaften (2002): Arbeitsgemeinschaft wissenschaftlich medizinischer Fachgesellschaften. S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms), www.awmf-online.de <reference>(1993) Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 149: 516–518
Geary ES, Dendinger TE, Freiha FS, Stamey TA (1995) Nerve sparing radical prostatectomy: a different view. J Urol 154:145–149
Gronberg H, Isaacs SD, Smith JR et al. (1997) Characteristics of prostate Cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. Jama 278:1251–1255
Gronberg H, Wiklund F, Damber JE (1999) Age specific risks offamilial prostate Carcinoma: a basis for Screening recommendations in high risk populations. Cancer 86:477–483
Hampson SJ, Davies JH, Charig CR, Shearer RJ (1993) LHRH analogues as primary treatment for urinary retention in patients with prostatic Carcinoma. Br J Urol 71:583–586
Hebert JR, Hurley TG, Olendzki BC et al. (1998) Nutritional and socioeconomic factors in relation to prostate cancer mortality: a crossnational study. J Natl Cancer Inst 90:1637–1647
Hoedemaeker RF, Rietbergen JB, Kranse R et al. (2000) Histopathological prostate cancer characteristics at radical prostatectomy after population based Screening. J Urol 164:411–415
Krebsregister (2002): Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland, 3. Aufl. Saarbrücken, www.rki.de
Lilja H (2001) Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer. Eur Urol 39 (Suppl 4): 47–48
Luboldt HJ, Rübben H (2000) PSA-Früherkennung des Prostatakarzinoms. Urologe A 39:22–26
Luboldt HJ, Altwein JE, Bichler KH et al. (1999) Früherkennung des Prostatakarzinoms. Erste Ergebnisse einer prospektiven multizentrischen Studie in Deutschland. Urol A 38:114–123
Murphy GP, Mettlin C, Menck H et al. (1994) National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 152:1817–1819
Neri R, Kassem M (1984) Biological and clinical properties of antiandrogens. Prog Cancer Res Ther 31:507–518
Oesterling J, Jacobsen S, Chute C et al. (1993) Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860–864
Ohori M, Goad JR, Wheeler TM et al. (1994) Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843–1849
Partin AW, Yoo J, Carter HB et al. (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150,110–114
Partin AW, Mangold LA, Lamm DM et al. (2001) Contemporary update of prostate cancer Staging nomograms (Partin Tables) for the new millennium. Urology 58:843–848
Pienta K ( 1997) Etiology, epidemiology and prevention of Carcinoma of the prostate. In: Walsh P et al. (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2489–2496
Pilepich MV, Caplan R, Byhardt RW et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis Carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol 15:1013–1021
Price CP, Allard J, Davies G et al. (2001) Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a Screening Programme for prostate cancer. Ann Clin Biochem 38:188–216
Scher HI, Kelly WK (1993) Flutamide withdrawal Syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566–1572
Schröder F (1997) Endocrine treatment of prostate cancer. In: Walsh P et al. (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2627–2644
Semjonow A, Zechel C, Brandt B et al. (1995) Teststreifenuntersuchungen. Prostataspezifisches Antigen (PSA). Urol A 34 (Suppl 1): 91
Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A (1995) Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154:424–428
Stenman U, Leinonen J, Alfthan H et al. (1991) A complex between prostate-specific antigen an alphal-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222–226
Tannock IF, Osoba D, Stockler MR et al. (1996) Chemotherapy with mitoxantrone plus Prednisone or Prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764
Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152:1831–1836
Adlercreutz H, Mazur W (1997) Phyto-oestrogens and Western diseases. Ann Mediane 29:95–120
Bratt O (2002) Hereditary prostate cancer: clinical aspects. J Urol 168: 906–913
Clark LC, Combs Jr GF, Turnbull BW et al. For the Nutritional Prevention of Cancer Study Group (1996) Effects of Selenium supplementation for cancer prevention in patients with Carcinoma of the skin: a randomized controlled clinical trial. JAMA 276:1957–1963
Corder EH, Guess HA, Hulka BS et al. (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467–472
Eichholzer, Stahelin HB, Gey KF, Ludin E, Bernasconi F (1996) Prediction of male cancer mortality by plasma levels of interacting Vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 66:145–150
Giovannucci E, Rimm EB, Colditz GA et al. (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85: 1571–1579
Hammerer P, Graefen M, Steuber T, Huland H (2000) Chemoprävention des Prostatakarzinoms. Urologe A 39:304–308
Hanchette CL, Schwartz GG (1992) Geographie patters of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer 70:2861–2869
Hartman TJ, Albanes D, Pietinen P et al. (1998) The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 7:335–340
Heinonen OP, Albanes D, Virtamo J et al. (1998) Prostate cancer and supplementation with a-tocopherol and ß-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446
Helzlsouer KJ, Huang HY, Alberg AJ et al. (2000) Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl cancer Inst 92:2018–2023
Hsing AW, Devesa SS (2001) Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23:3–13
Jankevicius F, Miller SM, Ackermann R (2002) Nutrition and risk of prostate cancer. Urol Int 68:69–80
Klein EC, Thompson IM, Lippman SM et al. (2001) SELECT: the next prostate cancer prevention trial. J Urol 166:1311–1315
Madersbacher S, Haidinger G, Temml C, Schmidbauer CP for the Prostate Study Group of the Austrian Society of Urology (1998) The prevalence of lower urinary tract Symptoms in Austria as assessed by an open survey of 2096 men. Eur Urol 34:136–141
Madersbacher S, Schatzl G, Gsur A et al. (2002) Spielen Phytoöstrogene eine Rolle in der Pathogenese des Prostatakarzinoms in westlichen Industrieländern. Urologe A (Suppl 1): S 5
McConnell JD, Bruskewitz R, Walsh P et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 338:557–563
Moyad MA (2002) Selenium and vitamin E Supplements for prostate cancer: evidence or embellishment. Urology 59 (Suppl 4A): 9–19
Nomura AM (2001) Body size and prostate cancer. Epidem Reviews 23:126–131
Oishi K, Okada K, Yoshida O et al. (1988) A case-control study of prostatic cancer with reference to dietary habits. Prostate 12: 179–190
Roehrborn CG, Boyle P, Nickel JC et al. for ARIA3001, ARIA3002 and ARIA3003 Study Investigators (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441
Schmitz-Dräger BJ, Savov O, Fischer C, Ebert T, Altwein J (2002) Ernährung und Prostatakrebs. Urologe B 42:28–292
Schulman CC, Anderson B, Bangma CH, Marberger MJ (2002) Prevention and Screening. Eur Urol (Suppl 1): 3–9
Vutuc C, Waldhoer T, Madersbacher S, Micksche M, Haidinger G (2001) Prostate cancer in Austria: impact of prostate-specific antigen teston incidence and mortality. Eur J Cancer Prev 10:425–428
Wang Y, Corr JG, Thaler HT et al. (1995) Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 87:1456–1462
Woolf CM (1960) An investigation of familial aspects of Carcinoma of the prostate. Cancer 13: 739–744
Altwein J (1998) Diagnostik, Klinik und Therapie. In: Helpap B, Rübben H (Hrsg) Das Prostatakarzinom. Pathologie, Praxis und Klinik. Springer, Berlin Heidelberg New York Tokio
Bairati I, Meyer F, Fradet Y, Moore L (1998) Dietary fat and advanced prostate cancer. J Urol 159:1271–1275
Behre HM (1994) Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 40: 341–349
Carson C, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61 (Suppl 1):2–7
Curran MJ, Bihrle W (1999) Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 53:423–424
Davies P, Eaton CL (1991) Regulation of prostate growth. J Endocrinol 131:5–9
Diemer T, Desjardins C (1999) Developmental and genetic disorders in spermatogenesis. Hum Reprod Update 5:120–140
Diemer T, Haies DB, Weidner W (2003) Immune-endocrine interactions and Leydig cell function: the role of cytokines. Andrologia 35:55–63
Feldman HA, Longcope C, Derby CA et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589–598
Ferri M, Norman RW (2000) Prostate cancer in a hypogonadal male receiving androgen supplementation. Can J Urol 7:1055–1056
Fowler JE Jr, Whitmore WF Jr (1981) The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126:372–375
Frick J, Jungwirth A, Rovan E (1998) Androgens and the prostate. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, Substitution. Springer, Berlin Heidelberg New York Tokio
Gann PH, Hennekens CH, Sacks FM et al. (1994) Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 86:281–286
Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD (2002) Prostatespecific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 23:922–926
Gruenewald DA, Matsumoto AM (2003) Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 51:101–115
Heikkila R, Aho K, Heliovaara M et al.(1999) Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate Carcinoma: a longitudinal study. Cancer 86:312–315
Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL (1988) The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57: 216–218
Hoffman MA, De Wolf WC, Morgentaler A (2000) Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163:824–827
Jin B, Conway AJ, Handelsmann DJ (20001) Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol 54:437–445
Krebsregister (1999): Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland: Häufigkeiten und Trends, 2. Aufl.
Moradi T, Delfino RJ, Bergstrom SR, Yu ES, Adami HO, Yuen J (1998) Cancer risk among Scandinavian immigrants in the US and Scandinavian residents compared with US whites, 1973–89. Eur J Cancer Prev 7:117–125
Morgentaler A, Brüning B, De Wolf WC (1996) Occult prostate cancer in men with low serum testosterone levels. JAMA 276:1904–1906
Oishi K, Yoshida O, Schroeder FH (1995) The geography of prostate cancer and its treatment in Japan. Cancer Surv 23:267–280
Oliver RT, Williams G, Paris AM, Blandy JP (1997) Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 49:79–82
Paiss G, Gschwend JE, Maier C, Eisele M, Vogel W, Nautmann RE, Nerkammer K (2002) Preventing prostata Carcinoma in men with familial disposition. Urologe A 41 (6): 596–601
Partin AW, Coffey DS (1998) The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh PC et al. (eds) Campbell’s Urology, 7th edn. Saunders, Philadelphia
Pollard M, Lückert PH (1986) Promotional effects of testosterone and high fat diet on the development of autochthonous prostate Cancer in rats. Cancer Lett 32:223–227
Prins GS, Birch L (1995) The developmental pattern of androgen receptor regulation in the rat prostate lobes is altered following neonatal exposure to estrogen. Endocrinology 136:1303–1314
Ribeiro M, Ruff P, Falkson G (1997) Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20:605–608
Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE (1992) 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339:887–889
Ross RK, Pike MC, Coetzee GA et al. (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58:4497–4504
Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA (1994) Association of energy and fat intake with prostate Carcinoma risk: results from The Netherlands Cohort Study. Cancer 86:1019–1027
Shaneyfelt T, Nascin R, Bubley G, Mantzoros CS (2000) Normonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18 (4): 847–853
Svetec DA, Canby ED, Thompson IM, Sabanegh ES Jr (1997) The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 158:1775–1777
Tenover JL (1997) Androgen administration to aging men. Endocrinol Metab Clin North Am 23:877–886
Tenover JL (1998) Androgen deficiency in aging men. Aging Male 1 (Suppl 1): 16–21
Thomas JA, Keenan EJ (1994) Effects of estrogens on the prostate. J Androl 15:571–575
Wilson DW, Harper ME, Jensen HM et al. (1985) Prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation. Prostate 7:131–141
Rights and permissions
Copyright information
© 2004 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Jocham, D. et al. (2004). Prostata. In: Männersprechstunde. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18705-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-18705-6_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-00915-3
Online ISBN: 978-3-642-18705-6
eBook Packages: Springer Book Archive